Fred Alger Management, LLC Tcr2 Therapeutics Inc. Transaction History

Fred Alger Management, LLC

  • $19.7 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$8.44 - $18.35 $750,602 - $1.63 Million
-88,934 Closed
0 $0
Q2 2021

Aug 16, 2021
SELL
$16.41 - $24.71 $62,489 - $94,095
-3,808 Reduced 4.11%
88,934 $1.46 Million
Q1 2021

May 17, 2021
SELL
$20.38 - $34.07 $440,534 - $736,457
-21,616 Reduced 18.9%
92,742 $2.05 Million
Q4 2020

Feb 16, 2021
BUY
$19.0 - $32.63 $2.17 Million - $3.73 Million
114,358 New
114,358 $3.54 Million

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email